Fagron press release

Regulated information Waregem (Belgium)/Rotterdam (The Netherlands)¹, 22 July 2016

Fagron receives claim with regard to acquisition of AnazaoHealth

Fagron NV announces today that a court case was filed on July 18th against Fagron NV (the "Company"), Fagron Holdings USA, LLC and certain former directors of the Company by one of the nine former owners of AnazaoHealth (acquired by Fagron in April 2015) in the U.S. District Court for the Middle District of Florida. The former owner is seeking damages in relation to the acquisition transaction somewhere in the range of US\$ 10 million to US\$ 20 million. Fagron contests all allegations and the entire claim and will respond in court to the allegations and claims made.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

For more information:

Constantijn van Rietschoten Chief Marketing Officer Tel. +31 6 53 69 15 85 constantijn.van.rietschoten@fagron.com

Fagron profile

Fagron is the leading global pharmaceutical compounding company, bringing customized pharmaceutical care to hospitals, pharmacies, clinics and patients in 32 countries worldwide.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol 'FAGR'. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

